Chinese researchers reportedly have applied for a local patent on an experimental Gilead drug that they believe could help fight the novel coronavirus outbreak - and also significantly bolster Gilead's bottom-line going forward.
The Wuhan Institute of Virology – based in the central Chinese city at the epicenter of the epidemic – has applied for a patent in China for the use of Remdesivir, an antiviral therapy used to treat infectious diseases including Ebola and SARS.
The application was made on Jan. 21 along with a military academy, according to a Feb. 4 statement on the institute’s website.
Chinese officials have moved aggressively to contain the infection that has killed almost 500 people and infected nearly 25,000. If granted, Gilead will need to get Chinese patent owners on board when it wants to sell the drug for treating the novel coronavirus infection outside China.
Of course, Gilead isn't alone in the race to find an antidote to the rapidly spreading virus.
Among the U.S. drug companies exploring a potential treatment: AbbVie (ABBV) - Get AbbVie, Inc. Report, Johnson & Johnson (JNJ) - Get Johnson & Johnson (JNJ) Report, Moderna (MRNA) - Get Moderna, Inc. Report and Novavax (NVAX) - Get Novavax, Inc. Report.
Shares of Gilead were down 2.37% at $65.80 in premarket trading on Wednesday.
Catch up on the Latest Videos on TheStreet!
- Where Does Tesla Stand Among World's Most Valuable Car Companies?
- 2020 Oscar Nominations: 'Joker' Leads With 11 Nods
- What Is Coronavirus?
- Here's How Stock Prices are Determined
- TheStreet Explains: How to Read an Analyst Note
- Retirement Daily: How to Find a Tax Preparer That’s Right For You
- Free Webinar: Expert Advice on Equity Trading by CME Group